title: [Bortezomib-induced peripheral neuropathy in multiple myeloma patients].
abstract: OBJECTIVE
  To describe the side effects of bortezomib in treatment of multiple myeloma (MM), especially the incidence of peripheral neuropathy (PN).
  
  
  METHODS
  Information of 107 patients with MM who were treated with bortezomib in the First Affiliated Hospital of Zhejiang University from 2009 to 2014, were collected and analyzed retrospectively, to analyze the occurrence of adverse events during the treatment, especially the incidences of PN in each cycle and in different patients.
  
  
  RESULTS
  A total of 40 (37%) patients suffered from PN, among which 13 patients were grade 3 PN and no patients reported grade 4 PN. Other common treatment-related side effects were thrombocytopenia, gastrointestinal reactions, fatigue, lung infection, herpes zoster in turn. In 44 MM patients treated strictly with bortezomib 1.3 mg/m(2) (days 1, 4, 8, 11) of each 3-week cycle, 20(45%) patients suffered from PN, of which 6 (14%) patients got grade 3 PN. In other 63 patients who received bortezomib less than 1.3 mg/m(2), 20 (32%) patients got PN and 7(11%) patients were grade 3 PN. There was no significant difference in the incidence of PN between the two groups of MM patients mentioned above (P=0.149), as well as the incidence of grade 3 PN (P=0.694). Univariate and multivariate analyse revealed that gender, age, a history of hypertensive disease, diabetes or hepatitis B virus infection, baseline PN symptoms and a history of neurotoxicity drug therapy were all not risk factors for PN (all P>0.05).
  
  
  CONCLUSIONS
  The reduction of bortezomib do not decrease the incidence of PN in bortezomib treatment of MM. Age, a history of diabetes and baseline PN symptoms are not risk factors for PN in bortezomib treatment of MM.
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Li
authors.initials: L
authors.lastname: Shao
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Shasha
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Haitao
authors.initials: H
authors.lastname: Meng
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Wenbin
authors.initials: W
authors.lastname: Qian
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Wenyuan
authors.initials: W
authors.lastname: Mai
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Wenjuan
authors.initials: W
authors.lastname: Yu
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Hongyan
authors.initials: H
authors.lastname: Tong
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Mao
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Juying
authors.initials: J
authors.lastname: Wei
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China.
authors.forename: Jiejing
authors.initials: J
authors.lastname: Qian
authors.affiliation: Department of Hematology, First Affiliated Hospital of Zhejiang University, Institute of Hematology, Key Laboratory for Hematology of Zhejiang Province, Hangzhou 310003, China; Email: jiej0503@163.com.
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000069286:Bortezomib / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D009101:Multiple Myeloma; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D012189:Retrospective Studies; D012307:Risk Factors; D013921:Thrombocytopenia
chemical_list: D000069286:Bortezomib